Skip to content

Study · Randomized controlled trial · n = 24 · 2019

7 results

Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2).

Wägner AM, Miranda-Calderín G, Ugarte-Lopetegui MA, Marrero-Santiago H, Suárez-Castellano L, López-Madrazo MJ, Alberiche-Ruano MP, Abselam Ahmed N, Alemán C, Castellot-Martín A, Díez Del Pino A, Nóvoa-Mogollón FJ

Diabetes & metabolism14 Sept 2018Cited by 23 (Europe PMC)

PMID30223083 (opens in a new tab)DOI10.1016/j.diabet.2018.08.010 (opens in a new tab)PepBankPUB-30223083
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, VO2max at 6 months did not differ between liraglutide and placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change peak exercise oxygen use compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeMaximum oxygen consumption (VO2max)
    Study

    n = 24

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.8 mg/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no differences in VO2max [17.98 (4.8) vs. 15.90 (4.96) mL/kg/min; P > 0.10], VE/VCO2 slope [30.18 (4.8) vs. 32 (4.49)], left ventricular ejection fraction or 6-min walk test [530.7 (86) vs. 503.9 (84) m] at 6 months.
    2 context sentences
    Summary · context
    In this phase-IV randomized double-blind placebo-controlled parallel-group clinical trial at a tertiary hospital, T2D patients with HbA1c levels of 7-10% with oral agents and/or intermediate-/long-acting insulin were allocated (computer-generated randomization, ratio 1:1) to either liragl…
    Summary · context
    A total of 24 patients (15 women) aged 52 (11.7) years, with diabetes duration of 8.7 (5.8) years, BMI 34.98 (6.2) kg/m2 and HbA1c 8.2% (0.68%), were randomized to liraglutide 1.8 mg daily or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, the VE/VCO2 slope at 6 months did not differ between liraglutide and placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change breathing efficiency in exercise compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeVE/VCO2 slope
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.8 mg/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no differences in VO2max [17.98 (4.8) vs. 15.90 (4.96) mL/kg/min; P > 0.10], VE/VCO2 slope [30.18 (4.8) vs. 32 (4.49)], left ventricular ejection fraction or 6-min walk test [530.7 (86) vs. 503.9 (84) m] at 6 months.
    2 context sentences
    Summary · context
    In this phase-IV randomized double-blind placebo-controlled parallel-group clinical trial at a tertiary hospital, T2D patients with HbA1c levels of 7-10% with oral agents and/or intermediate-/long-acting insulin were allocated (computer-generated randomization, ratio 1:1) to either liragl…
    Summary · context
    A total of 24 patients (15 women) aged 52 (11.7) years, with diabetes duration of 8.7 (5.8) years, BMI 34.98 (6.2) kg/m2 and HbA1c 8.2% (0.68%), were randomized to liraglutide 1.8 mg daily or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, left ventricular ejection fraction at 6 months did not differ between liraglutide and placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change the heart's pumping fraction compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeLeft ventricular ejection fraction
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no differences in VO2max [17.98 (4.8) vs. 15.90 (4.96) mL/kg/min; P > 0.10], VE/VCO2 slope [30.18 (4.8) vs. 32 (4.49)], left ventricular ejection fraction or 6-min walk test [530.7 (86) vs. 503.9 (84) m] at 6 months.
    2 context sentences
    Summary · context
    In this phase-IV randomized double-blind placebo-controlled parallel-group clinical trial at a tertiary hospital, T2D patients with HbA1c levels of 7-10% with oral agents and/or intermediate-/long-acting insulin were allocated (computer-generated randomization, ratio 1:1) to either liragl…
    Summary · context
    A total of 24 patients (15 women) aged 52 (11.7) years, with diabetes duration of 8.7 (5.8) years, BMI 34.98 (6.2) kg/m2 and HbA1c 8.2% (0.68%), were randomized to liraglutide 1.8 mg daily or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, 6-minute walk distance at 6 months did not differ between liraglutide and placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change walking distance in 6 minutes compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant change6-minute walk test distance
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.8 mg/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no differences in VO2max [17.98 (4.8) vs. 15.90 (4.96) mL/kg/min; P > 0.10], VE/VCO2 slope [30.18 (4.8) vs. 32 (4.49)], left ventricular ejection fraction or 6-min walk test [530.7 (86) vs. 503.9 (84) m] at 6 months.
    2 context sentences
    Summary · context
    In this phase-IV randomized double-blind placebo-controlled parallel-group clinical trial at a tertiary hospital, T2D patients with HbA1c levels of 7-10% with oral agents and/or intermediate-/long-acting insulin were allocated (computer-generated randomization, ratio 1:1) to either liragl…
    Summary · context
    A total of 24 patients (15 women) aged 52 (11.7) years, with diabetes duration of 8.7 (5.8) years, BMI 34.98 (6.2) kg/m2 and HbA1c 8.2% (0.68%), were randomized to liraglutide 1.8 mg daily or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, HbA1c was lower with liraglutide than with placebo at the end of the study.

    In plain wordsIn adults with type 2 diabetes, HbA1c was lower with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c at end of study
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    HbA1c was lower (6.7% vs. 7.7%; P =  0.005)
    2 context sentences
    Summary · context
    In this phase-IV randomized double-blind placebo-controlled parallel-group clinical trial at a tertiary hospital, T2D patients with HbA1c levels of 7-10% with oral agents and/or intermediate-/long-acting insulin were allocated (computer-generated randomization, ratio 1:1) to either liragl…
    Summary · context
    A total of 24 patients (15 women) aged 52 (11.7) years, with diabetes duration of 8.7 (5.8) years, BMI 34.98 (6.2) kg/m2 and HbA1c 8.2% (0.68%), were randomized to liraglutide 1.8 mg daily or placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, a trend towards lower maximum systolic blood pressure during ergometry with liraglutide was not statistically significant.

    In plain wordsIn adults with type 2 diabetes, liraglutide showed only a non-significant trend to lower peak blood pressure during exercise.

    Peptide
    Liraglutide
    Outcome
    No significant changeMaximum systolic blood pressure during ergometry
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.8 mg/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    with a trend towards lower maximum systolic blood pressure during ergometry [171.7 (24.4) vs. 192.5 (25.6); P = 0.052] in the liraglutide group at the end of the study.
    2 context sentences
    Summary · context
    In this phase-IV randomized double-blind placebo-controlled parallel-group clinical trial at a tertiary hospital, T2D patients with HbA1c levels of 7-10% with oral agents and/or intermediate-/long-acting insulin were allocated (computer-generated randomization, ratio 1:1) to either liragl…
    Summary · context
    A total of 24 patients (15 women) aged 52 (11.7) years, with diabetes duration of 8.7 (5.8) years, BMI 34.98 (6.2) kg/m2 and HbA1c 8.2% (0.68%), were randomized to liraglutide 1.8 mg daily or placebo.
  7. 07HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes, no severe adverse events were reported.

    In plain wordsIn adults with type 2 diabetes, no severe adverse events were reported in this trial.

    Peptide
    Liraglutide
    Outcome
    No significant changeSevere adverse events
    Study

    n = 24

    Outcome group
    Adverse events · Whole body
    Studied dose
    1.8 mg/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no severe adverse events.
    2 context sentences
    Summary · context
    In this phase-IV randomized double-blind placebo-controlled parallel-group clinical trial at a tertiary hospital, T2D patients with HbA1c levels of 7-10% with oral agents and/or intermediate-/long-acting insulin were allocated (computer-generated randomization, ratio 1:1) to either liragl…
    Summary · context
    A total of 24 patients (15 women) aged 52 (11.7) years, with diabetes duration of 8.7 (5.8) years, BMI 34.98 (6.2) kg/m2 and HbA1c 8.2% (0.68%), were randomized to liraglutide 1.8 mg daily or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.